13G Filing: Camber Capital Management and Amag Pharmaceuticals Inc. (AMAG)

Page 5 of 6 – SEC Filing

13G

CUSIP No.
00163U106
Page 5 of
6
 
(c) Number of
shares as to which such person has:
 
(i) Sole power to
vote or to direct the vote
Camber Capital
Management LLC – 0 shares
Stephen DuBois
– 0 shares
 
(ii) Shared power
to vote or to direct the vote
Camber Capital
Management LLC –
2,500,000
shares
Stephen DuBois
2,500,000
shares
 
(iii) Sole power to
dispose or to direct the disposition of
Camber Capital
Management LLC – 0 shares
Stephen DuBois
– 0 shares
 
(iv) Shared power
to dispose or to direct the disposition of
Camber Capital
Management LLC –
2,500,000
shares
Stephen DuBois
2,500,000
shares
 
 
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A
CLASS.
 
If this statement
is being filed to report the fact that as of the date hereof the
reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [
].
 
INSTRUCTION:
Dissolution of a group requires a response to this
item.
 
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON
BEHALF OF ANOTHER PERSON.
 
If any other person
is known to have the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of, such
securities, a statement to that effect should be included in
response to this item and, if such interest relates to more than
five percent of the class, such person should be identified. A
listing of the shareholders of an investment company registered
under the Investment Company Act of 1940 or the beneficiaries of
employee benefit plan, pension fund or endowment fund is not
required.
 
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF
THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
PARENT HOLDING COMPANY.
 
If a parent holding
company or Control person has filed this schedule, pursuant to Rule
13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an
exhibit stating the identity and the Item 3 classification of the
relevant subsidiary. If a parent holding company or control person
has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),
attach an exhibit stating the identification of the relevant
subsidiary.
 
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
MEMBERS OF THE GROUP.
 
If a group has
filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so
indicate under Item 3(j) and attach an exhibit stating the identity
and Item 3 classification of each member of the group. If a group
has filed this schedule pursuant to ss.240.13d-1(c) or
ss.240.13d-1(d), attach an exhibit stating the identity of each
member of the group.
 
ITEM 9. NOTICE OF DISSOLUTION OF
GROUP.
 
Notice of
dissolution of a group may be furnished as an exhibit stating the
date of the dissolution and that all further filings with respect
to transactions in the security reported on will be filed, if
required, by members of the group, in their individual capacity.
See Item 5.
 
 

Follow Amag Pharmaceuticals Inc. (NASDAQ:AMAG)